HIGHLIGHTS
- who: Ulla Olsson-Stru00f6mberg and colleagues from the University of have published the article: IFN-u03b1 with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia Translational Immunology Research Program, in the Journal: (JOURNAL)
- what: Next, the authors focused on the changes in immune 4 cell phenotypes induced by the addition of IFN-u03b1 to dasatinib therapy. scRNA-seq and flow cytometry data revealed that the combination therapy partly reversed the dasatinib-induced maturation of NK cells and CD8+ and CD4+ T_cells. The authors show that the combination of 2 immunomodulatory . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.